RxDoctor Payments Data

Krisstina Gowin, DO

Hematology · Irvine, CANPI 1477845089

Payments from drug & device makers

$484,482in general payments, 2019–2025

Across 244 payments — averaging $1985.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$248K
  • AbbVie$110K
  • Incyte Corporation$101K
  • Pfizer$21K
  • E.r. Squibb & Sons, L.L.C.$3K
  • Bristol Myers Squibb$233
  • plus $576 from 8 others

What the payments were for

  • Consulting fees$20,15131%
  • Speaking & faculty fees$33,95052%
  • Travel & lodging$9,68315%
  • Food & beverage$1,8623%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$484,482 in reported general payments places this provider in the 60th percentile of 178 hematology providers in California.

See all hematology providers in California

Medicare billing

Part B allowed, 2024
$30,849
Medicare patients
125
Services billed
280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide98$1,802,991
PomalystPomalidomide18$455,600
JakafiRuxolitinib Phosphate27$445,269
NinlaroIxazomib Citrate22$300,517
BesremiRopeginterferon Alfa-2b-Njft13$214,148
Lenalidomide14$193,308
EliquisApixaban41$29,906
Acyclovir102$1,306
Hydroxyurea30$1,192
Morphine Sulfate ErMorphine Sulfate21$777
Oxycodone Hcl19$481
Gabapentin26$304
Dexamethasone18$271
Morphine Sulfate11$247
Pregabalin22$227

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$233$1,802,99198 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$3,200$455,60018 claims
Incyte CorporationJakafi$101,432$445,26927 claims
Takeda Pharmaceuticals U.S.A., Inc.Ninlaro$65$300,51722 claims
PfizerEliquis$21,215$29,90641 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 178 hematology providers in California.

Other hematology in Irvine

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →